|
Products |
| Products |
|
Diseases |  |
News |  |
| «12...1213141516171819202122...39313932» |
- Rituxan (rituximab) / Roche
Low Yield of Routine Serological Screening for Hepatitis B in Patients with Rheumatoid Arthritis Starting Rituximab Therapy in a Non-Endemic Country (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3289;
Also no patient developed an RTX related HBV reactivation. Routine serological screening for HBV therefore seems redundant in a low-risk population, and HBV testing should be reserved for patients with known risk factors.
- iscalimab (CFZ533) / Novartis
Associations Between Protein Quantitative Trait Loci and Risk of Primary Sj (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3253;
Routine serological screening for HBV therefore seems redundant in a low-risk population, and HBV testing should be reserved for patients with known risk factors. We provided genetic evidence further elucidating the complexity of primary Sj
- Rituxan (rituximab) / Roche
Mortality and Its Predictor Variables in Patients with Sj (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3234;
Older age, history of heart failure, hypocomplementemia C4, increase of ESR and lung involvement were independent risk factors associated with increased mortality. More attention should be paid to those patients with poor prognostic factors.
- Rituxan (rituximab) / Roche
Damage Accrual Predicts the Development of Lymphoma in Primary Sjogren's Syndrome (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3209;
Compared to patients who did not developed lymphoma, those who did were more frequently prescribed cyclophosphamide (31.3% vs 1.6%, p< 0.001), rituximab (56.3% vs 3.2%, p< 0.001) and steroids (68.8% vs 35.8%, p 0.01), including high doses of steroids (75.0% vs 32.4%, p 0.002). Cumulative and evolving damage in the first years of disease should raise concern about the possible development of lymphoma in patients with pSS.
- Rituxan (rituximab) / Roche
Reduction in Circulating Neutrophil Extracellular Traps and Restored Degradation Post-treatment in Pediatric Lupus (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3160;
Understanding mechanisms of NETosis in pSLE may allow for the development of new therapies targeting NET degradation. Studies investigating the presence of NETs at the end organ using renal biopsy specimens are currently underway.
- Orencia (abatacept) / BMS
Childhood-onset Sj (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3139;
While adult-onset SjD is characterized by peripheral CD4+ T-cell lymphopenia, we detected an opposite trend towards significant expansion of CD4+ T-cell subset frequencies in cSjD. This could have significant therapeutic implications, suggesting that cSjD may recapitulate the early phase of the corresponding adult disease phenotype, when treatments with T-cell targeted (such as abatacept, low dose IL2) or broader (such as leflunomide or cyclosporine A) effects could be beneficial.
- Rituxan (rituximab) / Roche
Characteristics, Treatment Responses and Prognosis in a Single Center Cohort of SLE Patients with Thrombocytopenia (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3114;
Patients with aPL positivity have higher risk for relapse. Since relapse is associated with higher damage, prevention is important.
- dapirolizumab pegol (CDP7657) / Biogen, UCB, Nektar Therap
Inhibitory Effects of Dapirolizumab Pegol, a Monovalent Anti-CD40L PEG-Conjugated Antigen-Binding Fragment Lacking a Functional Fc Domain, on In Vitro T Follicular Helper/B Cell Interactions and Cytokine Production in Systemic Lupus Erythematosus (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3089;
P3
DZP was shown to inhibit key germinal center-relevant cell interactions leading to suppression of cytokine and total and antigen-specific IgG production in vitro. These data support clinical and transcriptomic/proteomic findings from patients with SLE treated with DZP, where reductions of immunoglobulins and key pro-inflammatory cytokines have been observed.4
- Rituxan (rituximab) / Roche
Frequency and Associated Factors of Herpes Zoster Infection in Systemic Lupus Erythematosus Patients from Latin-America (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2999;
Neurological compromise and the use of immunosuppressants such as methotrexate and mycophenolate were associated with the occurrence of these events. It is important to be aware of the risk of HZ in SLE patients.
- Ibrance (palbociclib) / Pfizer
Identification of Co-expressed Molecular Markers That Predict Risk of Severe Flare in Patients with Systemic Lupus Erythematosus (SLE) (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2996;
P3
This work enhances our understanding of molecular predictors for severe SLE flares in the context of clinical trials. The findings also suggest potential new pathways for targeted treatment strategies.
- Darzalex (daratumumab) / J&J, FT522 / Fate Therap, Rituxan (rituximab) / Roche
Development of a Multiplexed-engineered, Off-the-shelf CAR NK Cell with Unique Multi-Pathogenic Cell Targeting Capacity for the Treatment of Autoimmune Diseases in the Absence of Conditioning Chemotherapy (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2985;
FT522 is currently being investigated in a Phase 1 clinical study in B cell lymphoma, including without administration of CCT to patients. A multi-indication investigational new drug (IND) application is being prepared for the treatment of AI Dz.
- Orencia (abatacept) / BMS
M5542: A Potent CD80, CD86, and OX40L Antagonist Fusion Molecule for the Treatment of Autoimmune Diseases (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2982;
M5542, single agent comparators abatacept (CTLA4Ig) and anti-OX40L, or the combination thereof were tested for their ability to inhibit proinflammatory cytokine production in a mixed lymphocyte reaction (MLR) of activated monocyte-derived dendritic cells (MDDCs) and T-cells from healthy donors or SLE peripheral blood mononuclear cells (PBMCs)... M5542 effectively blocked CD28 and OX40 mediated T-cell activation and reduced T-cell driven inflammation, demonstrating promise in treating autoimmune diseases.
- ianalumab (VAY736) / Novartis
Ianalumab Induced Durable Depletion of Circulating B Cell Subsets and Associated Changes in B Cell and Neutrophil Transcriptomic and Proteomic Profiles in Patients with Systemic Lupus Erythematosus: 52-Week Treatment Results from a Phase 2 Trial (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2977;
P2
At W52, responders of SRI-4 with sustained, tapered and CS showed a significant decrease in the IFN gene signature score vs non responders. As neutrophils associate with extracellular trap formation and contribute to autoantibody and type I IFN production, our results also provide further characterization of disease modification pathways by ianalumab.
- KYV-101 / Kyverna
Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Induces Multicompartmental B Cell Depletion in Peripheral Blood, Bone Marrow and Lymph Nodes of Systemic Lupus Erythematosus (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2970;
In SLE, anti-CD19 CAR T cell therapy enables broad, tissue-based depletion of B cells in the peripheral blood, bone marrow and lymph nodes 16 weeks post-treatment. These findings support the notion that anti-CD19 CAR T cell therapy induces remission in patients with SLE through complete and sustained depletion of autoreactive B cells within primary and secondary lymphatic organs.
- dapirolizumab pegol (CDP7657) / Biogen, UCB, Nektar Therap
Dapirolizumab Pegol Impacts Important Immunologic Pathways in Systemic Lupus Erythematosus: Pharmacodynamic Analysis of T Cell and Antigen Presenting Cell Pathways from a Phase 2b Trial (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2959;
P2, P3
Beyond its known effects on B cells and IFN signaling,7 these data demonstrate targeted effects of DZP on T cell activation, antigen presentation, and proinflammatory cytokines, such as IFN-?, involved in adaptive immune responses related to SLE. These findings support the broad mechanism of action of DZP in modulating multiple aspects of SLE immunopathology.
- peresolimab (LY3462817) / Eli Lilly
Exhausted T-cells Are Increased in Autoimmune Diseases and Predict Response to Anti-TNF in RA and SPA Patients (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2943;
Exhausted T-cells are differentially enriched between IMIDs. Sj
- Rituxan (rituximab) / Roche
2nd Analysis of IgG4-Related Disease in a Diverse Long Island Population: Utilizing Serological and Histological Markers for Assessing Treatment Response (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2933;
Sj While IgG4 levels and ratios (IgG4/IgG and IgG4/IgG1) were much lower after Rituximab, these markers did not distinguish between responders and non-responders
- nintedanib / Generic mfg.
Nintedanib in Autoimmune Disease-related Interstitial Lung Disease: Real-life Effectiveness, Safety and Tolerance in a Spanish Multicenter Study (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2930;
In our cohort, despite the great heterogeneity, NINTE appears to prevent interstitial lung progression in all subgroups regardless of the type of AD, concomitant treatment or time since diagnosis of pulmonary involvement. UIP pattern, ACCP antibodies, cardiological comorbidity, ILD exacerbation and DLCO% value at 6 months were linked to mortality.
- Blincyto (blinatumomab) / Astellas, Amgen, Actemra IV (tocilizumab) / Roche, JW Pharma, Tecvayli (teclistamab-cqyv) / Genmab, J&J
Safety of Bispecific T-cell Engager Therapy in Autoimmune Disease (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2895;
Treatment with bispecific T-cell engagers had a favorable safety profile in 12 patients with refractory autoimmune disease. Hence, targeting CD19 or BCMA with T cell engagers appears feasible in autoimmune disease and warrants further clinical development.
- Rituxan (rituximab) / Roche
Clinico-Immunological Profile and Treatment Outcomes of Clinically Significant Diaphragmatic Weakness in Patients with Idiopathic Inflammatory Myopathies: Results from the Largest Single-Center Cohort of 16 Cases (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2868;
Unexplained or disproportionate dyspnea should raise the suspicion of diaphragmatic involvement. DUS is a useful, non-invasive tool for rapid, bedside assessment in admitted patients.
- Rituxan (rituximab) / Roche
Evaluating the Efficacy of Rituximab in the Treatment of Refractory Adult Idiopathic Inflammatory Myositis Using Total Improvement Score: Data from a Real-World Multi-Centre Registry in the United Kingdom (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2835;
P2, P2/3,
DUS is a useful, non-invasive tool for rapid, bedside assessment in admitted patients. Using TIS in an observational setting, we have demonstrated that patients receiving RTX are more likely to respond to treatment than patients receiving conventional immunosuppressants, despite them having longer disease duration and failing more therapies.
- Rituxan (rituximab) / Roche
IVIG Treatment Duration in Immune-mediated Necrotizing Myopathy and a Possible Association of Vacuolar Changes with Black/African American Female Patients (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2831;
There was no specific duration that prevented flares. The positive correlation with flares suggests that flares prompted providers to treat longer with IVIG.
- Humira (adalimumab) / AbbVie, Rituxan (rituximab) / Roche
Insights into Rheumatology Practice in Uganda (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2781;
The spectrum of available laboratory testing is extensive. Oral DMARDs are the mainstay of therapy, whereas biologics are not regularly used.
- Rituxan (rituximab) / Roche
The National Trend of Using Prescription Immunosuppressives (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2721;
In this nationally representative sample, reported prescription medications commonly used as immunosuppressants within the preceding month were less prevalent than previously reported. However, the increasing trend in using immunosuppressants was confirmed in the current report.
- methotrexate / Generic mfg.
Efficacy and Safety of Methotrexate in Immune Checkpoint Inhibitor-induced Arthritis: A Retrospective Longitudinal Monocentric Study (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2673;
Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 was used to describe the oncologic outcomes of the patients at first year. We evaluated 16 patients (M/F = 6/10, mean age 63.4 years) affected by melanoma (62.5%), colo-rectal cancer (25%) and lung cancer (12.5%) receiving anti-PD1 (pembrolizumab in 33%, nivolumab in 33%, cemiplimab in 7%, nivolumab + pembrolizumab in 7%), PDL1 (atezolizumab in 13%) and/or CTLA4 blockers (ipilimumab + nivolumab in 7%).Polyarthritis occurred in 56% of patients, oligo-arthritis in 37% and a polymyalgia rheumatica-like syndrome in 7% after a mean onset time of 60
- Assessing Major Adverse Cardiovascular Events (MACE) Risk in Common Rheumatology Treatments (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2671;
We evaluated 16 patients (M/F = 6/10, mean age 63.4 years) affected by melanoma (62.5%), colo-rectal cancer (25%) and lung cancer (12.5%) receiving anti-PD1 (pembrolizumab in 33%, nivolumab in 33%, cemiplimab in 7%, nivolumab + pembrolizumab in 7%), PDL1 (atezolizumab in 13%) and/or CTLA4 blockers (ipilimumab + nivolumab in 7%).Polyarthritis occurred in 56% of patients, oligo-arthritis in 37% and a polymyalgia rheumatica-like syndrome in 7% after a mean onset time of 60 The focus was on the association of MACE
- Comparison of COVID-19 Infection and Mortality Rates in Vaccinated and Unvaccinated Patients with Autoimmune Inflammatory Rheumatic Disease (AIRD) Using Conventional and Biologic DMARD Therapy at an Urban Tertiary Care Hospital (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2669;
Despite high vaccination rates, vaccinated individuals had a higher incidence of COVID-19, likely due to other factors. Specific immunotherapies such as abatacept (7.1%) and mycophenolate (6.5%) were associated with higher mortality rates, emphasizing the need for careful monitoring.
- Disease Flare Following Immune Checkpoint Inhibition in Patients with Cancer and Preexisting Vasculitis (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2662;
The outcomes were favorable, as patients responded well to flare treatment, which enabled the continuation of ICI therapy after achieving clinical stability. Prior vasculitis in patients without disease activity should not be considered an absolute contraindication for cancer immunotherapy with ICI.
- Tecentriq (atezolizumab) / Roche
Gout FlaresFollowingImmune Checkpoint Inhibitors Treatment (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2651;
While flares may certainly occur in patients with gout as a part of the natural history of this disease, the high frequency of flares after ICI therapy warrants additional investigation. Larger studies with control populations not treated with ICIs are needed to further understand the increased flare risk following ICI treatment in gout patients.
- Orencia (abatacept) / BMS
Use of Abatacept for the Treatment of Severe Immune-related Adverse Events from Immune Checkpoint Inhibitors for Cancer: A Case Series (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2645;
All patients who received abatacept were male, and nearly all received this for myocarditis, with onset soon after ICI initiation. Nearly half died while hospitalized, and only 2/9 are still alive.
- Effects of JAK Inhibitors on Subsets of the Innate Immune System (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2636;
The inhibition of the JAK-STAT pathway by jakinibs affects innate immune cells differently than biological DMARDs, resulting in a decrease in cytotoxic activated NK cells and intermediate monocytes, which may explain side effects such as viral infections and potential neoplasia. Additionally, JAK-STAT inhibition shifts T-helper cell subsets towards a more exhausted phenotype.
- Dupixent (dupilumab) / Sanofi, Regeneron
Induction of Systemic Inflammatory Diseases with Dupilumab Therapy (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2634;
Dupilumab appears to be associated with de novo or relapse of systemic inflammatory diseases. These include eosinophilic granulomatosis with polyangiitis, seronegative arthritis, cutaneous granulomatosis, sarcoidosis, giant cell arteritis, Addison's disease, Sj
- Rituxan (rituximab) / Roche
Complications and Treatment Use Associated with Long-term Oral Corticosteroid Therapy Among Patients with Dermatomyositis or Polymyositis (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2633;
Findings highlight the limitations of OCS and further support unmet need among these patients. Disease management with novel treatments with advantageous safety profile utilized in the disease course may be clinically impactful.
- Rheumatic Complications Post-CAR-T Cell Therapy. Experience of a Single Center (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2625;
Patients treated with anti-CD19 CAR-T therapy (ARI-0001, (A3B1)4-1BB/CD3? ) and anti
- Orencia (abatacept) / BMS, Olumiant (baricitinib) / Eli Lilly, Actemra IV (tocilizumab) / Roche, JW Pharma
Approach to Janus Kinase Inhibition for Juvenile Dermatomyositis Among Childhood Arthritis and Rheumatology Research Alliance (CARRA) and Paediatric Rheumatology European Society (PReS) Providers (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2624;
Most providers who have used JAKi have seen clinical improvement in their patients. Major barriers to the use of JAKi include lack of clinical data and insurance coverage.
- Rituxan (rituximab) / Roche
Association of Disease-Modifying Anti-Rheumatic Drug Selection with Hospitalized Infection in Youth with Childhood-Onset Systemic Lupus Erythematosus (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2615;
Among children with LN, those who received cyclophosphamide had more infections than those who received mycophenolate, which persisted after adjusting for baseline differences between groups and concomitant medications including oral corticosteroid dose. Higher oral corticosteroid doses were associated with increased hospitalized infection risk among those without LN.
- Rituxan (rituximab) / Roche
Therapeutic Drug Monitoring (TDM) of Rituximab to Predict Early B-Cell Repopulation in Children (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2605;
This allows us to predict when individuals will achieve subtherapeutic rituximab levels which can help determine when to re-treat with rituximab and quantify an individualized wash-out period when needed. The data obtained will be used to build a population PK model to further understand the PK variations observed in participants.
- Soliris (eculizumab) / AstraZeneca, Rituxan (rituximab) / Roche
Acute Transverse Myelitis in Pediatric Systemic Lupus Erythematosus (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2591;
Even with maximal therapy, neurologic outcomes were sub-optimal. Future directions may include better correlation of clinical phenotype with imaging findings (white vs.
- Rituxan (rituximab) / Roche
Unlocking Insights into Juvenile Dermatomyositis: Clinical and Demographic Profiles Paired with Total Improvement Scores at a Tertiary Center (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2589;
In our cohort, MDA5 was the most common antibody detected, and the majority of patients experienced moderate TIS improvement. The outcomes underscore the severity of the disease, with three fatalities highlighting the need for timely diagnosis, aggressive treatment, and close monitoring.
- Tavneos (avacopan) / Amgen, Rituxan (rituximab) / Roche
Using Case-Based Continuing Education to Identify and Address Knowledge and Behavior Gaps in ANCA-associated Vasculitis (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2565;
There was a lack of consensus regarding when to use GC tapering and for how long to keep patients on maintenance therapy. While the education provided had a robust impact on knowledge and confidence, these findings highlight the need for subsequent education regarding evidence-based practices for patient assessment and how to incorporate steroid-sparing regimens into practice.
- Orencia (abatacept) / BMS, Rituxan (rituximab) / Roche
A Systematic Review of Treatment Strategies in VEXAS Syndrome (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2562;
The most common treatments tried in VEXAS include IL-6 inhibitors, IL-1 inhibitors, JAK inhibitors, azacytidine, and glucocorticoid monotherapy. Most patients required co-administration of glucocorticoids (more than 10 mg of prednisone) to help manage their disease activity.
- Orencia (abatacept) / BMS
Co-stimulatory Blockade Causes Targeted Quantitative and Clonotypic Contractions in Extrafollicular B-cell Subsets in Seropositive RA Patients (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2557;
Our findings are consistent with abatacept causing preferential therapeutic effects on extrafollicular B cells that include DN2 cells, recently implicated as major RA-associated autoantibody producers in rheumatoid joints. Supported in part by funds from BMS.
- Rituxan (rituximab) / Roche
Effects of Cumulative Rituximab Exposure in Patients with Rheumatoid Arthritis: Results from Cohort at a Tertiary Academic Health Care Setting (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2554;
Nevertheless, the risk for infection-related hospital admissions peaks during the first year of administration and is higher with concurrent prednisolone. Cumulative Rituximab exposure and serum IgG levels
- Characterizing Infusion-Related Reactions in Patients with Rheumatoid Arthritis Treated with Biologic DMARDs: Observations from the KOBIO Registry (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2542;
For patients with these risk factors, abatacept or tocilizumab may be considered as preferred options. These findings underscore the need for careful monitoring and tailored therapeutic strategies to enhance patient outcomes.
- Comparable Malignancy Risk of Janus Kinase Inhibitors with Conventional Synthetic and Biologic DMARDs in Asian Patients with Rheumatoid Arthritis: A Comprehensive Analysis from Two Medical Centers (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2536;
The results indicate that the risk of malignancies did not exhibit statistically significant differences among Asian RA patients treated with csDMARD-only, JAKi, and other bDMARD regimens, except for a potential association of rituximab with a lower incidence. However, it's important to note that regular cancer screenings are still advisable for these patients while they are undergoing JAKi/biologic treatment.
- Rituxan (rituximab) / Roche
Overview of Lung Manifestations in Sarcoidosis and Various Treatment Approaches at a University Center (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2530;
Extrapulmonary organ involvement was prevalent, underscoring the systemic nature of the disease. Limitations include the small sample size and potential benefits of incorporating detailed measures like serial PFT findings to enhance outcomes.
- Ituxredi (rituximab biosimilar) - Dr. Reddy's, Abbott, EMD Serono, CinnaGen, Fresenius Kabi, R / Pharm, Rituxan (rituximab) / Roche
Comparing Immunogenicity and Safety Following Transition from Reference Rituximab to Biosimilar Rituximab (DRL_RI) in Patients with Rheumatoid Arthritis: A Randomized, Double-blind, Phase 3 Study (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2518;
Immunogenicity was low and comparable in RA patients transitioning to DRL_RI or continuing RP/RMP. The overall safety profile in patients transitioning to DRL_RI did not differ in frequency, severity from patients continuing RP/RMP and was consistent with the known safety profile of rituximab.
- Humira (adalimumab) / AbbVie, Rituxan (rituximab) / Roche
Consequences of Switching Originator Biological Therapies to Its Biosimilars in Patients with Immune-mediated Diseases in a Mexican Cohort (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2511;
Switching of originator biological therapies to its biosimilar in our cohort of patients might not have an impact on efficacy or the incidence of infections; however, one of the most common AEs was associated with the mechanics of the autoinjector device. Although this may seem a minor issue, it led to patients missing a dose, thus having an impact on treatment compliance and thus the activity of the disease.
- Rituxan (rituximab) / Roche
Clinical Outcomes and Predictors of Relapse in Patients with IgG4-Related Disease Treated with Rituximab: A Real-World Experience (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2506;
We confirmed prior observations and identified novel risk factors for relapse, including female sex and salivary gland disease. Given that IgG4-RD is more common and severe in males, the finding of a lower risk of relapse among male patients in this study is intriguing.
- Humira (adalimumab) / AbbVie
Using Adalimumab Serum Concentration to Choose a Subsequent DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment (ADDORA-switch): Results of a Blinded Randomized Test Treatment Trial (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2495;
1.0 mg/L were switched to a non-TNFi b/tsDMARD...In both groups the specific non-TNFi b/tsDMARD, chosen at the discretion of the treating physician, could be abatacept, rituximab, sarilumab, tocilizumab, or a Janus kinase inhibitor... A switching strategy based on adalimumab trough serum concentration was not superior to random switching in RA patients failing adalimumab treatment.